[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100573784":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":29,"centralContacts":34,"locations":39,"responsibleParty":94,"collaborators":24,"id":96,"slug":97,"hasResults":98,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":22,"eligibilityCriteria":102,"healthyVolunteers":98,"sex":103,"minAge":104,"maxAge":24,"enrollmentInfo":105,"targetDuration":24,"studyType":108,"phases":109,"briefSummary":111,"conditions":112,"keywords":114,"overallStatus":42,"whyStopped":24,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":129},{"fullName":5,"class":6},"Beijing Tsinghua Chang Gung Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Atorvastatin group","EXPERIMENTAL","According to routine clinical practice, patients with dyslipidemia with prediabetes were given atorvastatin at a dose of 20 mg qd；",[13],"Drug: Atorvastatin",{"label":15,"type":10,"description":16,"interventionNames":17},"Xuezhikang group","The Xuezhikang group takes Xuezhikang at a dose of 600 milligrams twice a day, orally after meals;",[18],"Drug: Xuezhikang",[20,25],{"type":21,"name":22,"description":16,"armGroupLabels":23,"otherNames":24},"DRUG","Xuezhikang",[15],null,{"type":21,"name":26,"description":27,"armGroupLabels":28,"otherNames":24},"Atorvastatin","The atorvastatin group takes atorvastatin 20mg once a day, orally after meals.",[9],[30],{"name":31,"affiliation":32,"role":33},"lixia jin, phD","Beijing Tsinghua Changgeng Hospital","PRINCIPAL_INVESTIGATOR",[35],{"name":31,"role":36,"phone":37,"phoneExt":24,"email":38},"CONTACT","086-13810971045","jlxa00159@btch.edu.cn",[40,59,84],{"facility":41,"status":42,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"Beiqijia Community Health Service Center, Changping District, Beijing","RECRUITING","Beijing","Beijing Municipality","102209","China","CN",{"type":49,"coordinates":50},"Point",[51,52],116.39723,39.9075,{"lat":52,"lon":51},[55],{"name":56,"role":36,"phone":57,"phoneExt":24,"email":58},"yuchen hu","086-18701636194","562546856@qq.com",{"facility":60,"status":42,"city":43,"state":44,"zip":61,"country":46,"countryCode":47,"cosmosGeoPoint":62,"geoPoint":64,"contacts":65},"Beijing Tsinghua Changgung Hospital","102218",{"type":49,"coordinates":63},[51,52],{"lat":52,"lon":51},[66,67,71,74,76,78,80,82],{"name":31,"role":36,"phone":37,"phoneExt":24,"email":38},{"name":68,"role":36,"phone":69,"phoneExt":24,"email":70},"wenhui zhao, phD","086-13810719795","zwha01637@btch.edu.cn",{"name":72,"role":73,"phone":24,"phoneExt":24,"email":24},"IANZHONG XIAO, phD","SUB_INVESTIGATOR",{"name":75,"role":73,"phone":24,"phoneExt":24,"email":24},"CHENXIANG CAO, phD",{"name":77,"role":73,"phone":24,"phoneExt":24,"email":24},"CONG DENG, bachelor",{"name":79,"role":73,"phone":24,"phoneExt":24,"email":24},"BINBIN HAO, bachelor",{"name":81,"role":73,"phone":24,"phoneExt":24,"email":24},"ZHAOXIANG LIU, phD",{"name":83,"role":73,"phone":24,"phoneExt":24,"email":24},"LUQI XIAO, phD",{"facility":85,"status":42,"city":43,"state":44,"zip":24,"country":46,"countryCode":47,"cosmosGeoPoint":86,"geoPoint":88,"contacts":89},"Xiaotangshan Community Health Service Center, Changping District, Beijing",{"type":49,"coordinates":87},[51,52],{"lat":52,"lon":51},[90],{"name":91,"role":36,"phone":92,"phoneExt":24,"email":93},"Jiangtao Lu","086-136813163253","liujiangtaoyx@126.com",{"type":95,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR","100573784","phase-4-the-effects-of-xuezhikang-and-atorvastatin-on-lipid-in-patients-with-dyslipidemia-and-prediabetes-100573784",false,"NCT06750783","The Effects of Xuezhikang and Atorvastatin on Lipid in Patients With Dyslipidemia and Prediabetes","A Randomized Controlled Study on the Effects of Xuezhikang and Atorvastatin on Blood Glucose and Lipid Levels in Patients With Dyslipidemia and Prediabetes","Inclusion Criteria:\n\n* Age ≥ 18 years old;\n* No gender restrictions;\n* Definition of pre diabetes: All subjects were tested with 75g OGTT to measure fasting and 2h venous serum glucose and glycosylated hemoglobin. Fasting blood glucose ≥ 6.1 and \\\u003C 7mmol\u002FL, 2-hour serum glucose ≥ 7.8 and \\\u003C 11.1mmol\u002FL after glucose load, and glycated hemoglobin\\\u003C6.5%;\n* Abnormal lipid metabolism: LDL-c ≥ 3.4 mmol\u002FL and\\\u003C4.9 mmol\u002FL, and TG ≤ 5.6 mmol\u002FL; (2) Non-HDL-c ≥ 4.1mmol\u002FL and\\\u003C5.7 mmol\u002FL, and TG ≤ 5.6 mmol\u002FL;\n* Voluntarily sign the informed consent form.\n\nExclusion Criteria:\n\n* Patients who have met the diagnosis of diabetes;\n* Within 3 months prior to signing the informed consent form, there was an acute coronary syndrome, stroke, or transient ischemic attack.\n* ALT\u002FAST\\>3 times ULN;\n* Known myopathy, rhabdomyolysis, or creatine kinase levels greater than 4-fold ULN, and not caused by muscle injury;\n* Pregnant or planning to conceive;\n* Have used any lipid-lowering drugs within 3 months;\n* Individuals with allergies\u002Fcontraindications to Xuezhikang and Atorvastatin.\n* Suffering from any of the following diseases: uncontrolled hyperthyroidism and hypothyroidism, severe heart failure, malignant tumors, hematopoietic system diseases, digestive system diseases affecting digestion and\u002For absorption function, mental disorders, other serious or unstable physical diseases.\n* History of alcohol or drug abuse or dependence within 3 months prior to joining the trial.\n* Participated in clinical trials of other drugs or devices within 3 months prior to joining the trial.\n* Researchers believe that other situations are not suitable for participating in the experiment.","ALL","18 Years",{"count":106,"type":107},398,"ESTIMATED","INTERVENTIONAL",[110],"PHASE4","This study compares the impact of Xuezhikang and atorvastatin on glucose metabolism to explore the incidence of prediabetes patients developing diabetes after 24 weeks of Xuezhikang use, and by investigating the effect of Xuezhikang on blood glucose fluctuations, discusses the possible mechanisms by which Xuezhikang affects glucose metabolism.",[113],"Prediabetic State (IGT)",[115,116,117,118,119],"XUEZHIKANG","atorvastatin","glucose metabolism","blood glucose fluctuations","diabetes","2025-04-01",{"date":122,"type":123},"2025-04-03","ACTUAL",{"date":125,"type":123},"2024-12-31",{"date":127,"type":107},"2026-03-31",{"name":5,"class":6},3]